Get the latest news, insights, and market updates on ALEC (Alector, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Alector Showcases ABC Brain-Delivery Platform, AL137 and AL050 Updates at TD Cowen Conference
Alector (NASDAQ:ALEC) used a presentation at the 46th Annual TD Cowen Healthcare Conference to highlight progress on its Alector Brain Carrier (ABC) platform, which is designed to deliver multiple therapeutic “cargos” across the blood-brain barrier using the transferrin receptor (TfR). Eric Brown, h Mar 4, 2026 - $ALEC
How The Alector (ALEC) Story Is Shifting As Analyst Targets And Sector Views Evolve
Alector’s story on Wall Street has shifted slightly, with one key analyst moving the price target from US$0.75 to US$0.90 while the fair value estimate remains at $2.10. That tweak lines up with fresh commentary that links Alector to a wider group of U.S. small and mid cap biotechs that some expect could gradually move toward funding themselves as big pharma peers approach a patent cliff. As you read on, you will see how this updated target fits into the evolving analyst narrative and what it... Mar 4, 2026 - $ALEC
Alector (ALEC) Reports Q4 Loss, Beats Revenue Estimates
Alector (ALEC) delivered earnings and revenue surprises of +13.71% and +103.43%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock? Feb 26, 2026 - $ALEC
Alector Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Advancing the Alector Brain Carrier (ABC) platform across multiple therapeutic modalities, including antibodies, enzymes, and siRNA, with continued progress across AL137 (ABC-enabled anti-amyloid antibody for Alzheimer’s Disease), AL050 (ABC-enabled GCase Enzyme Replacement Therapy for Parkinson’s Disease) and AL064 (ABC-enabled Tau siRNA for Alzheimer’s Disease) Independent interim futility analysis of the PROGRESS-AD Phase 2 trial of nivisnebart (AL101) in early Alzheimer’s disease expected in Feb 25, 2026 - $ALEC
Alector: Q4 Earnings Snapshot
SOUTH SAN FRANCISCO, Calif. AP) — Alector Inc. ALEC) on Wednesday reported a loss of $37.3 million in its fourth quarter. Feb 25, 2026 - $ALEC
Alector to Participate in the TD Cowen 46th Annual Health Care Conference
SOUTH SAN FRANCISCO, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that management will participate in a corporate presentation at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026, at 3:10 pm ET. A live webcast of the corporate presentation will be available on the “Events & Presentations” page wi Feb 24, 2026 - $ALEC
What The New Sector Driven Price Target Means For Alector's Story And Valuation
The new US$0.90 price target for Alector sits below the unchanged US$2.10 fair value estimate, and the small adjustment in the discount rate reflects how analysts are tying the story more closely to broader expectations for U.S. small and mid cap biotech names. Behind that shift is a view that some companies in this group could move from heavy capital use toward stronger cash generation, while still leaving room for caution on Alector’s own execution and long term growth risks. Stay tuned to... Feb 18, 2026 - $ALEC
Global Market Stocks With Estimated Value Opportunities In February 2026
As global markets navigate a complex landscape marked by the Federal Reserve's steady interest rates and fluctuating consumer confidence, investors are keenly observing sectors where value stocks have outperformed their growth counterparts. In this environment, identifying undervalued stocks with strong fundamentals and potential for appreciation becomes crucial, offering opportunities to capitalize on market inefficiencies. Feb 6, 2026 - $ALEC
How The Narrative Around Alector (ALEC) Is Shifting After Index Removal And New Targets
Alector’s latest research update keeps the stock under an Underweight rating while lifting the price target to US$0.90 from US$0.75, a mix that captures both hesitation and a bit more optimism on what the company could be worth. The fair value anchor is unchanged at 2.1 and the revenue growth assumption still points to about a 50.08% decline. However, a slightly lower discount rate and higher net profit margin input help explain why analysts are comfortable nudging their valuation reference... Feb 3, 2026 - $ALEC
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple